Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
Ernexa Therapeutics released preclinical data showing its lead candidate ERNA-101 achieved 100% survival and complete tumor elimination in ovarian cancer models when combined with PD-1 blockade. The study demonstrated that ERNA-101 remodels the tumor microenvironment from immunosuppressive to immune-activated, driving robust T cell activity and sustained anti-tumor responses.
Key figures
- Drug Name
- ERNA-101
- Phase Of Trial
- Preclinical
- Survival rate
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.